Immunome Reports Increased Q1 Net Loss Amidst Key Pipeline Advancements and Varegacestat NDA Submission
IMNM has more than doubled off its 52-week low of $7.42.
Summary
Immunome Inc. reported an increased net loss of $53.8 million for Q1 2026, with cash and equivalents decreasing to $582.7 million. However, the company achieved a significant regulatory milestone by submitting a New Drug Application for varegacestat and advanced several other oncology candidates.
Key Events · Earnings and Guidance · IMNM
-
Increased Net Loss
Immunome reported a net loss of $53.8 million for the three months ended March 31, 2026, an increase from $41.6 million in the same period last year.
-
Cash Position and Runway
Cash and cash equivalents decreased to $582.7 million as of March 31, 2026, from $653.5 million at December 31, 2025. The company projects its existing cash will fund operations for at least 12 months.
-
Varegacestat NDA Submission
The company submitted a New Drug Application (NDA) for varegacestat to the FDA in April 2026, following positive Phase 3 RINGSIDE trial results. A Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) is planned by the end of 2026.
-
Pipeline Progression
Immunome is advancing multiple oncology candidates, including IM-1021 (Phase 1 ongoing with objective responses), IM-3050 (Phase 1 initiated in March 2026), and IM-1617 (IND clearance in April 2026, Phase 1 planned for Q2 2026).
Analysis · IMNM · Life Sciences
Immunome Inc. reported a significant increase in its net loss for the first quarter of 2026, reflecting ongoing high research and development costs typical for a clinical-stage biotechnology company. Despite the increased cash burn, the company maintains a cash runway of at least 12 months. Critically, Immunome achieved a major regulatory milestone by submitting a New Drug Application for varegacestat to the FDA, following positive Phase 3 results. This moves their lead candidate closer to potential commercialization. The continued progression of other oncology candidates through early-stage clinical trials and IND clearances also highlights a robust development pipeline, balancing the negative financial performance with strong operational execution.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMNM was trading at $22.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $7.42 to $27.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.